Novo Nordisk’s Wegovy Pill Gets EU Panel Backing for Approval
The EMA panel recommended approval of Novo Nordisk’s oral Wegovy, a key regulatory milestone that expands the company’s obesity franchise into non-injectable treatment in Europe. The recommendation validates semaglutide’s oral formulation and positions Novo to capture a broader patient base, supporting revenue growth projections. Peak sales estimates for the oral pill exceed $10 billion, and the shares rallied premarket on the news.
- ▲ EMA CHMP positive opinion on Wegovy oral
- ▲ Potential European Commission approval within months
- ▼ Competition from Eli Lilly's orforglipron progressing in trials
- ▼ Pricing and reimbursement challenges in European markets
▼ Show FAQ (3) ▲ Hide FAQ
How significant is this EMA recommendation for Novo Nordisk?
It is a crucial step toward commercializing the oral obesity drug in Europe, a region with high obesity prevalence. The recommendation validates the drug's safety and efficacy, potentially unlocking billions in annual sales.
Will this approval cannibalize sales of Novo's injectable Wegovy?
Unlikely, as the pill addresses a different patient segment—those who avoid injections—and may expand the total addressable market rather than substitute existing users.
What is the estimated market size for oral obesity drugs in Europe?
Analysts project the global obesity drug market to exceed $20 billion by 2030, with oral formulations capturing a significant share due to convenience and patient preference.